Corona Remedies has debuted at Rs 1452.00 on the BSE, up by 390 points or 36.72% from its issue price of Rs 1062.00.
The scrip is currently trading at Rs. 1474.60, up by 412.6 points or 38.85% from its issue price.
It has touched a high and low of Rs. 1499.00 and Rs. 1430.10 respectively. So far 9.79 lakh shares were traded on the counter.
The offering, which was open for subscription between December 08, 2025 and December 10, 2025 was subscribed 144.54 times. The issue price was fixed at Rs 1062.00 per share i.e. at upper end of price band of Rs 1008-1062 apiece.
Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: